BACKGROUND: The use of a bupivicaine pain pump has previously been reported to lower costs to hospitals, while providing similar pain relief to opioid-based patient controlled analgesia (PCA) pumps. However, these benefits have not been investigated in laparoscopic bariatric surgery. METHODS: We prospectively randomized 40 laparoscopic Roux-en-Y gastric bypass (LRYGBP) patients into two groups. The first group received the ON-Q bupivicaine pain pump placed subxiphoid and radiating in both directions caudally beneath the lowest rib. The second group was treated with a meperidine PCA, which was initiated in the PACU and discontinued at 06:00 hrs the following morning. Both groups had identical surgery, anesthesiologists, anesthesia protocol and postoperative nausea prophylaxis. RESULTS: There were no significant differences between the groups with regard to age, sex, pain scores, nausea scores, gas pain scores, antiemetic use throughout their stay, or opioid use in the PACU. However, there was a dramatic decrease in opioid use between the two groups over the time interval from leaving the PACU to 06:00 hrs (meperidine by PCA mean 217 mg vs ON-Q 129 mg meperidine equivalents, P=0.008). CONCLUSIONS: The use of a bupivicaine pain pump offers the opportunity to dramatically reduce the use of opioids postoperatively in all bariatric patients by eliminating PCA. This change could potentially reduce the incidence of respiratory failure from oversedation, while offering the same levels of pain control.
RCT Entities:
BACKGROUND: The use of a bupivicainepain pump has previously been reported to lower costs to hospitals, while providing similar pain relief to opioid-based patient controlled analgesia (PCA) pumps. However, these benefits have not been investigated in laparoscopic bariatric surgery. METHODS: We prospectively randomized 40 laparoscopic Roux-en-Y gastric bypass (LRYGBP) patients into two groups. The first group received the ON-Q bupivicainepain pump placed subxiphoid and radiating in both directions caudally beneath the lowest rib. The second group was treated with a meperidine PCA, which was initiated in the PACU and discontinued at 06:00 hrs the following morning. Both groups had identical surgery, anesthesiologists, anesthesia protocol and postoperative nausea prophylaxis. RESULTS: There were no significant differences between the groups with regard to age, sex, pain scores, nausea scores, gas pain scores, antiemetic use throughout their stay, or opioid use in the PACU. However, there was a dramatic decrease in opioid use between the two groups over the time interval from leaving the PACU to 06:00 hrs (meperidine by PCA mean 217 mg vs ON-Q 129 mg meperidine equivalents, P=0.008). CONCLUSIONS: The use of a bupivicainepain pump offers the opportunity to dramatically reduce the use of opioids postoperatively in all bariatric patients by eliminating PCA. This change could potentially reduce the incidence of respiratory failure from oversedation, while offering the same levels of pain control.
Authors: Kern Singh; Dino Samartzis; Dino Samartzis Dip; James Strom; David Manning; Marion Campbell-Hupp; F Todd Wetzel; Pernendu Gupta; Frank M Phillips Journal: Spine (Phila Pa 1976) Date: 2005-11-15 Impact factor: 3.468
Authors: Daniel P Lemanu; Sanket Srinivasa; Primal P Singh; Sharon Johannsen; Andrew D MacCormick; Andrew G Hill Journal: Obes Surg Date: 2012-06 Impact factor: 4.129
Authors: Saskia L Boerboom; Ann de Haes; Lianne Vd Wetering; Edo O Aarts; Ignace M C Janssen; Jose W Geurts; Ed T Kamphuis Journal: Obes Surg Date: 2018-10 Impact factor: 4.129
Authors: Rafael Moncada; Linas Martinaitis; Manuel Landecho; Fernando Rotellar; Carlos Sanchez-Justicia; Manuel Bellver; Magdalena de la Higuera; Camilo Silva; Beatriz Osés; Elena Martín; Susana Pérez; Jose Luis Hernandez-Lizoain; Gema Frühbeck; Victor Valentí Journal: Obes Surg Date: 2016-02 Impact factor: 4.129
Authors: Kemal Dogan; Linda Kraaij; Edo O Aarts; Parweez Koehestanie; Edwin Hammink; Cees J H M van Laarhoven; Theo J Aufenacker; Ignace M C Janssen; Frits J Berends Journal: Obes Surg Date: 2015-01 Impact factor: 4.129